Kura Oncology, Inc. (KURA)

9.70 +0.09 (+0.94%) USD  |  NASDAQ  |  Oct 15, 16:00
9.84 +0.14 (+1.44%) After-Hours: 20:00
More

Kura Oncology Cash from Operations (TTM) : -111.76M for June 30, 2026

Cash from Operations (TTM) Chart

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -111.76M
March 31, 2026 -77.98M
December 31, 2025 -64.06M
September 30, 2025 87.80M
June 30, 2025 124.99M
March 31, 2025 111.23M
December 31, 2024 134.32M
September 30, 2024 -169.12M
June 30, 2024 -154.71M
March 31, 2024 -137.80M
December 31, 2023 -124.82M
September 30, 2023 -117.05M
June 30, 2023 -109.03M
March 31, 2023 -113.75M
December 31, 2022 -110.06M
September 30, 2022 -106.90M
June 30, 2022 -110.48M
March 31, 2022 -108.22M
December 31, 2021 -104.55M
September 30, 2021 -99.49M
June 30, 2021 -91.86M
March 31, 2021 -78.52M
Date Value
December 31, 2020 -69.83M
September 30, 2020 -65.46M
June 30, 2020 -60.63M
March 31, 2020 -60.33M
December 31, 2019 -54.76M
September 30, 2019 -51.04M
June 30, 2019 -51.89M
March 31, 2019 -50.06M
December 31, 2018 -48.66M
September 30, 2018 -45.92M
June 30, 2018 -39.15M
March 31, 2018 -32.67M
December 31, 2017 -28.44M
September 30, 2017 -27.70M
June 30, 2017 -26.94M
March 31, 2017 -26.66M
December 31, 2016 -25.35M
September 30, 2016 -24.22M
June 30, 2016 -23.17M
March 31, 2016 -21.12M
December 31, 2015 -17.92M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Inovio Pharmaceuticals, Inc. -80.58M
Fortress Biotech, Inc. 120.36M
Spero Therapeutics, Inc. 19.58M
Gossamer Bio, Inc. -164.59M
ACADIA Pharmaceuticals, Inc. 160.32M